BRCA May Affect Triple-Neg's Response to Carboplatin Before Sx

Moderators

Triple-Negative Breast Cancer's Response to Carboplatin Before Surgery Seems Affected By BRCA1/2 Mutation Status
July 14, 2017
In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen. Read more...